SCHEMBL441219

SCHEMBL441219

CCC(CC(=O)CC(=O)O)c1ccc2cc(OC)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 9/20 0.59
AKR1C2 P52895 9/20 0.59
PTGS1 P23219 4/20 0.59
AKR1C1 Q04828 1/20 0.59
PTGS2 P35354 3/20 0.52
TSHR P16473 2/20 0.52
CDC42 P60953 1/20 0.52
RAC1 P63000 1/20 0.52
CYP1A2 P05177 1/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
FFAR1 O14842 3/20 0.50
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALOX5 P09917 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
ABCB11 O95342 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15782118 0.82 AKR1C3 (0.62) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL15782117 0.77 AKR1C3 (0.56) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL15780716 0.76 AKR1C3 (0.55) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL4453571 0.75 FFAR1 (0.78) AKR1C3AKR1C2PTGS1AKR1C1FFAR1
SCHEMBL10587177 0.75 AKR1C3 (0.70) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL11225278 0.75 L3MBTL1 (0.51) FFAR1L3MBTL1LMNAMAPT
SCHEMBL13828208 0.75 AKR1C3 (0.54) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL24991971 0.75 AKR1C3 (1.00) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL3043390 0.75 AKR1C3 (1.00) AKR1C3AKR1C2PTGS1AKR1C1PTGS2
SCHEMBL3967988 0.75 ABCB11 (0.67) AKR1C3AKR1C2PTGS1AKR1C1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065179-A1 PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, Ytemiska Institutet AB (SE) 2012-03-15 US disclosed
EP-2419398-A1 A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, Ytkemiska Institutet AB (SE) 2012-02-22 EP disclosed
WO-2010120232-A1 A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, YTKEMISKA INSTITUTET AB (SE) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065179-A1 PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY BCKDK, KHK, CA7 AKR1C3 131/4885AKR1C2 41/4885PTGS1 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.